Jump to content

KannaLife: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Undid revision 795731042 by Jytdog (talk) - We are undoing this revision because the editor who did it did it maliciously. Kannalife is a well documented, completely separate company and should not have been merged with Medical Marijuana, Inc. We see that the user that did this has been discredited so please allow this change or contact us for further questions.
Tags: Removed redirect Undo
OAbot (talk | contribs)
Bots
441,761 edits
m Open access bot: add pmc identifier to citation with #oabot.
Line 22: Line 22:
In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref>
In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref>


Kannalife is currently conducting research and development at the [[Pennsylvania Biotechnology Center of Bucks County]]<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/kannalife-in-r-amp-d-collaboration-for-cannabinoid-based-drugs/81248179/ |title=Kannalife in R&D Collaboration for Cannabinoid-Based Drugs |publisher=Genengnews.com |date= |accessdate=2013-04-04}}</ref> in Doylestown, PA, for a target drug candidate, [[KLS-13019]]<ref name=Kinney-2016>{{cite journal|author1=William A. Kinney |author2=Mark E. McDonnell |author3=Hua Marlon Zhong |author4=Chaomin Liu |author5=Lanyi Yang |author6=Wei Ling |author7=Tao Qian |author8=Yu Chen |author9=Zhijie Cai |author10=Dean Petkanas |author11=Douglas E. Brenneman |title=Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability|journal=ACS Med. Chem. Lett.|doi=10.1021/acsmedchemlett.6b00009}}</ref> to treat [[Hepatic encephalopathy]] and [[Chronic traumatic encephalopathy|CTE]],<ref>{{cite web|url=http://www.foxnews.com/health/2014/11/10/medical-marijuana-company-developing-drug-to-protect-nfl-players-brains/ |title=Medical marijuana company developing drug to protect NFL players’ brains |last=Mulvihill Moran |first=Jessica |date=November 9, 2014 |work=Fox News |accessdate=2014-11-09}}</ref> an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.
Kannalife is currently conducting research and development at the [[Pennsylvania Biotechnology Center of Bucks County]]<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/kannalife-in-r-amp-d-collaboration-for-cannabinoid-based-drugs/81248179/ |title=Kannalife in R&D Collaboration for Cannabinoid-Based Drugs |publisher=Genengnews.com |date= |accessdate=2013-04-04}}</ref> in Doylestown, PA, for a target drug candidate, [[KLS-13019]]<ref name=Kinney-2016>{{cite journal|author1=William A. Kinney |author2=Mark E. McDonnell |author3=Hua Marlon Zhong |author4=Chaomin Liu |author5=Lanyi Yang |author6=Wei Ling |author7=Tao Qian |author8=Yu Chen |author9=Zhijie Cai |author10=Dean Petkanas |author11=Douglas E. Brenneman |title=Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability|journal=ACS Med. Chem. Lett.|doi=10.1021/acsmedchemlett.6b00009|pmc=4834656 }}</ref> to treat [[Hepatic encephalopathy]] and [[Chronic traumatic encephalopathy|CTE]],<ref>{{cite web|url=http://www.foxnews.com/health/2014/11/10/medical-marijuana-company-developing-drug-to-protect-nfl-players-brains/ |title=Medical marijuana company developing drug to protect NFL players’ brains |last=Mulvihill Moran |first=Jessica |date=November 9, 2014 |work=Fox News |accessdate=2014-11-09}}</ref> an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.


Kannalife was featured in [[Sports Illustrated]] article on using cannabinoids to treat [[chronic traumatic encephalopathy|CTE]]. <ref>{{cite web|url=http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife |title=How cannabis is helping one company research treatment of CTE |date=July 12, 2016|work=Sports Illustrated}}</ref>
Kannalife was featured in [[Sports Illustrated]] article on using cannabinoids to treat [[chronic traumatic encephalopathy|CTE]]. <ref>{{cite web|url=http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife |title=How cannabis is helping one company research treatment of CTE |date=July 12, 2016|work=Sports Illustrated}}</ref>

Revision as of 21:00, 5 August 2019

KannaLife Sciences Inc.
Company typePrivate
IndustryPharmaceutical
Founded2010
FoundersDean Petkanas, Thoma Kikis
HeadquartersDoylestown, Pennsylvania And Huntington, New York
Total assetsExclusive License of patent US 6630507 
Websitehttp://kannalife.com
KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507  “Cannabinoids as Antioxidants and Neuroprotectants."

Kannalife Sciences Inc. is a bio-pharmaceutical and phyto-medical company based in Huntington, NY and Doylestown, Pennsylvania founded by Dean Petkanas and Thoma Kikis.[1] Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. It is a portfolio company of Medical Marijuana, Inc..[2]

In 2011, the company was granted an Exclusive License[3] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507 , “Cannabinoids as Antioxidants and Neuroprotectants."[4]

Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[5] in Doylestown, PA, for a target drug candidate, KLS-13019[6] to treat Hepatic encephalopathy and CTE,[7] an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.

Kannalife was featured in Sports Illustrated article on using cannabinoids to treat CTE. [8]

References

  1. ^ Guion, Payton (November 12, 2014). "The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage". VICE News. Retrieved 2014-12-12.
  2. ^ Leland, John (October 31, 2014). "For Pot Inc., the Rush to Cash In Is Underway". The New York Times. Retrieved 2014-10-31.
  3. ^ "Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans". federalregister.gov. Retrieved 2011-11-17.
  4. ^ "Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT)". thestreet.com. Retrieved 2012-07-09.
  5. ^ "Kannalife in R&D Collaboration for Cannabinoid-Based Drugs". Genengnews.com. Retrieved 2013-04-04.
  6. ^ William A. Kinney; Mark E. McDonnell; Hua Marlon Zhong; Chaomin Liu; Lanyi Yang; Wei Ling; Tao Qian; Yu Chen; Zhijie Cai; Dean Petkanas; Douglas E. Brenneman. "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Med. Chem. Lett. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656.
  7. ^ Mulvihill Moran, Jessica (November 9, 2014). "Medical marijuana company developing drug to protect NFL players' brains". Fox News. Retrieved 2014-11-09.
  8. ^ "How cannabis is helping one company research treatment of CTE". Sports Illustrated. July 12, 2016.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=KannaLife&oldid=909503269"